SCHEMBL6017769

SCHEMBL6017769

CCOC(=O)c1nc(-c2ccccc2N2CCOCC2)n(C)c(=O)c1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.47
RXFP1 Q9HBX9 1/20 0.45
GABRG2 P18507 4/20 0.44
GABRB3 P28472 4/20 0.44
GABRA5 P31644 4/20 0.44
GABRA1 P14867 2/20 0.44
GABRA3 P34903 2/20 0.44
GABRA2 P47869 1/20 0.44
LMNA P02545 2/20 0.43
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MTOR P42345 2/20 0.41
PIK3CA P42336 1/20 0.41
AKT1 P31749 1/20 0.41
POLB P06746 2/20 0.41
MAPT P10636 1/20 0.41
DNMT1 P26358 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6093597 0.80 HTT (0.52) ALDH1A1KDM4EL3MBTL1RXFP1LMNA
SCHEMBL6017847 0.79 GABRG2 (0.41) ALDH1A1KDM4EGABRG2GABRB3GABRA5
SCHEMBL6017752 0.78 KCNE1 (0.49) ALDH1A1KDM4ELMNAHPGDHSD17B10
SCHEMBL6018051 0.78 ALDH1A1 (0.44) ALDH1A1KDM4ERXFP1GABRG2GABRB3
SCHEMBL6017820 0.77 PIK3CD (0.41) ALDH1A1PIK3CAMAPT
SCHEMBL6017888 0.77 MAPT (0.41) ALDH1A1KDM4ELMNAPOLBMAPT
SCHEMBL6018490 0.77 LMNA (0.45) LMNAHPGD
SCHEMBL6018046 0.73 KDM4E (0.42) ALDH1A1KDM4ERXFP1GABRG2GABRB3
SCHEMBL18395687 0.72 L3MBTL1 (0.57) ALDH1A1KDM4EL3MBTL1RXFP1LMNA
SCHEMBL6017629 0.72 LMNA (0.48) ALDH1A1KDM4ERXFP1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037908-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2006-05-02 US disclosed
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US disclosed
WO-2004096128-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex DUT, CDK6, TYMS ALDH1A1 633/4885KDM4E 736/4885L3MBTL1 4018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.